Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer

NCT03728361 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

55

Enrollment

OTHER

Sponsor class

Conditions

Grade I Neuroendocrine Carcinoma
Grade II Neuroendocrine Carcinoma
Grade III Neuroendocrine Carcinoma
Metastatic Neuroendocrine Carcinoma
Neuroendocrine Carcinoma
Recurrent Small Cell Lung Carcinoma
Refractory Small Cell Lung Carcinoma
Lung Cancer Stage IV
Large Cell Neuroendocrine Carcinoma
Neuroendocrine Tumors
Small Cell Lung Cancer Metastatic
Small-cell Lung Cancer

Interventions

BIOLOGICAL: Nivolumab
DRUG: Temozolomide

Sponsor

Dwight Owen

Collaborators

[object Object]